TY  - GEN
AU  - Fountzilas,George
AU  - Valavanis,Christos
AU  - Kotoula,Vassiliki
AU  - Eleftheraki,Anastasia G
AU  - Kalogeras,Konstantine T
AU  - Tzaida,Olympia
AU  - Batistatou,Anna
AU  - Kronenwett,Ralf
AU  - Wirtz,Ralph M
AU  - Bobos,Mattheos
AU  - Timotheadou,Eleni
AU  - Soupos,Nikolaos
AU  - Pentheroudakis,George
AU  - Gogas,Helen
AU  - Vlachodimitropoulos,Dimitrios
AU  - Polychronidou,Genovefa
AU  - Aravantinos,Gerasimos
AU  - Koutras,Angelos
AU  - Christodoulou,Christos
AU  - Pectasides,Dimitrios
AU  - Arapantoni,Petroula
TI  - HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy
SN  - 1479-5876
PY  - 2012///0518
KW  - Adult
KW  - Aged
KW  - Antibiotics, Antineoplastic
KW  - pharmacology
KW  - Antigens, Neoplasm
KW  - genetics
KW  - Breast Neoplasms
KW  - drug therapy
KW  - Chemotherapy, Adjuvant
KW  - DNA Topoisomerases, Type II
KW  - DNA-Binding Proteins
KW  - Dose-Response Relationship, Drug
KW  - Epirubicin
KW  - Female
KW  - Gene Expression Profiling
KW  - Gene Expression Regulation, Neoplastic
KW  - drug effects
KW  - Genes, Neoplasm
KW  - Humans
KW  - Ki-67 Antigen
KW  - metabolism
KW  - Middle Aged
KW  - Multivariate Analysis
KW  - Paraffin Embedding
KW  - Poly-ADP-Ribose Binding Proteins
KW  - Proportional Hazards Models
KW  - RNA, Messenger
KW  - Receptor, ErbB-2
KW  - Receptors, Estrogen
KW  - Receptors, Progesterone
KW  - Risk Factors
KW  - Tissue Fixation
KW  - Treatment Outcome
KW  - Young Adult
N1  - Publication Type: Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1186/1479-5876-10-10
ER  -